Related Experiment Videos
Similarity/equivalence trials for combination vaccines
1National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892, USA.
Annals of the New York Academy of Sciences
|May 31, 1995
Summary
This study explains how to design vaccine trials to show a combination vaccine is similar to separate vaccines. The key is to rule out significant differences, ensuring clinical acceptability and appropriate sample sizes.
Area of Science:
- Vaccinology
- Clinical Trial Design
- Biostatistics
Background:
- Combination vaccines aim for convenience and comparable outcomes to separate vaccines.
- Similarity trials (equivalence trials) are crucial for regulatory approval and clinical adoption.
- Establishing similarity requires specific statistical approaches beyond superiority testing.
Purpose of the Study:
- To outline the statistical principles for designing similarity trials for combination vaccines.
- To emphasize the importance of clinically meaningful margins (theta 0) in trial design.
- To differentiate appropriate hypothesis testing for similarity versus superiority.
Main Methods:
- Designing trials to rule out superiority of separate components by a predefined margin (theta 0).
- Utilizing confidence intervals for estimation, which is often more relevant than hypothesis testing.
- Formulating sample size calculations based on appropriate null hypotheses for similarity.
Main Results:
- Rejection of the null hypothesis (separate components are superior by at least theta 0) supports vaccine similarity.
- Using a "no difference" null hypothesis is inappropriate for similarity trials and can lead to incorrect conclusions and inefficient sample sizes.
- Sample size calculations are available for various outcome measures, including means, proportions, and hazards.
Conclusions:
- Similarity trials for combination vaccines should focus on demonstrating that the combination is not worse than separate components beyond a clinically acceptable margin.
- Appropriate statistical design, including hypothesis formulation and sample size calculation, is critical for valid conclusions in vaccine equivalence studies.